Aditum Bio

Aditum is the Latin word for "access," and our mission is to give patients access to medicines that may not otherwise be developed. Aditum Bio is a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum Bio brings together unmatched scientific and domain expertise, combined with operational capabilities. Our agile operating model enables rapid company formation, planning and execution for a new model of drug development . We target clinic-ready therapies to help underserved patient populations, rapidly forming companies and staffing them with medical and scientific experts. Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum Bio currently manages a broad portfolio of clinical stage companies. For more information, please visit www.aditumbio.com.